The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours

被引:27
作者
Barrios, Carlos H. [1 ]
Blackstein, Martin E. [2 ]
Blay, Jean-Yves [3 ]
Casali, Paolo G. [4 ]
Chacon, Matias [5 ]
Gu, Jin [6 ]
Kang, Yoon-Koo [7 ]
Nishida, Toshirou [8 ]
Purkayastha, Das [9 ]
Woodman, Richard C. [9 ]
Reichardt, Peter [10 ]
机构
[1] PUCRS Sch Med, Porto Alegre, RS, Brazil
[2] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[3] Univ Lyon 1, F-69365 Lyon, France
[4] Ist Nazl Tumori, I-20133 Milan, Italy
[5] Alexander Fleming Inst, Dept Med Oncol, Buenos Aires, DF, Argentina
[6] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
[7] Univ Ulsan, Coll Med, Seoul, South Korea
[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba 2778577, Japan
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] HELIOS Klinikum Berlin Buch, D-13125 Berlin, Germany
关键词
CD117 (c-KIT)-positive gastrointestinal stromal tumour (GIST); Global cancer registry; Imatinib; Tyrosine kinase inhibitor; Long-term outcomes; Patient management; Mutational analysis; Localised; Advanced; Adjuvant; ESMO CLINICAL RECOMMENDATIONS; POPULATION-BASED INCIDENCE; IMATINIB MESYLATE; FOLLOW-UP; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; DOSE IMATINIB; PHASE-III; DIAGNOSIS; GIST;
D O I
10.1016/j.ejca.2015.07.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal sarcomas. This global, prospective registry followed patients with advanced or localised GIST (2007-2011). Methods: Current and evolving diagnostics, treatments and outcome measures in patients with GIST were assessed. Eligible patients were diagnosed with advanced or localised GIST within 15 months of registry entry. No treatment plan was prescribed, and no visit schedule was mandated. Treating physicians recorded patient information, including tumour response, diagnostic methods, medications, surgeries performed, mutation status and adverse events leading to dose/medication changes. Survival outcomes were estimated using the Kaplan-Meier method. Other data were analysed using descriptive statistics. Results: The registry included 1663 patients (advanced GIST, n = 1095; localised GIST, n = 537). Medications (e.g. tyrosine kinase inhibitor use and dosing), disease progression or recurrence and physician assessment of response to treatment in registry patients were consistent with controlled trials and prevailing clinical recommendations. In advanced GIST, estimated 30-month progression-free survival (PFS) (59.8%) and overall survival (OS) (82.7%) were higher than results from previously reported trials (approximate to 40% and approximate to 70%, respectively). Consistent with treatment guidelines, the most common initial treatments were imatinib for advanced GIST, and complete surgical resection for localised GIST. Computed tomography scans were the most common imaging technique used at diagnosis and follow-up. Mutation analysis was performed at diagnosis in only 15.3% and 14.5% of patients with advanced and localised GIST, respectively. Conclusions: In this real-world GIST registry, patients with advanced GIST were treated with imatinib and patients with localised GIST received surgical resection, in accordance with prevailing clinical recommendations. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:2423 / 2433
页数:11
相关论文
共 35 条
  • [1] [Anonymous], 2012, GLEEVEC
  • [2] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Blanke, Charles D.
    Demetri, George D.
    von Mehren, Margaret
    Heinrich, Michael C.
    Eisenberg, Burton
    Fletcher, Jonathan A.
    Corless, Christopher L.
    Fletcher, Christopher D. M.
    Roberts, Peter J.
    Heinz, Daniela
    Wehre, Elisabeth
    Nikolova, Zariana
    Joensuu, Heikki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 620 - 625
  • [3] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [4] Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Blay, J.-Y.
    Le Cesne, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 27 - 29
  • [5] Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183
  • [6] Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Blay, Jean-Yves
    Blomqvist, Carl
    Bonvalot, Sylvie
    Boukovinas, Ioannis
    Casali, Paolo G.
    De Alava, Enrique
    Dei Tos, Angelo Paolo
    Dirksen, Uta
    Duffaud, Florence
    Eriksson, Mikael
    Fedenko, Alexander
    Ferrari, Andrea
    Ferrari, Stefano
    Garcia del Muro, Xavier
    Gelderblom, Hans
    Grimer, Robert
    Gronchi, Alessandro
    Hall, Kirsten Sundby
    Hassan, Bass
    Hogendoorn, Pancras
    Hohenberger, Peter
    Issels, Rolf
    Joensuu, Heikki
    Jost, Lorenz
    Jurgens, Heribert
    Kager, Leo
    Le Cesne, Axel
    Leyvraz, Serge
    Martin, Javier
    Merimsky, Ofer
    Nishida, Ofer
    Picci, Piero
    Reichardt, Peter
    Rutkowski, Piotr
    Schlemmer, Marcus
    Sleijfer, Stefan
    Stacchiotti, Silvia
    Taminiau, Antoine
    Wardelmann, Eva
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 49 - 55
  • [7] Blay JY, 2012, DISCOV MED, V13, P357
  • [8] Consensus meeting for the management of gastrointestinal stromal tumors - Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    Blay, JY
    Bonvalot, S
    Casali, P
    Choi, H
    Debiec-Richter, M
    Dei Tos, AP
    Emile, JF
    Gronchi, A
    Hogendoorn, PCW
    Joensuu, H
    Le Cesne, A
    Mac Clure, J
    Maurel, J
    Nupponen, N
    Ray-Coquard, I
    Reichardt, P
    Sciot, R
    Stroobants, S
    van Glabbeke, M
    van Oosterom, A
    Demetri, GD
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (04) : 566 - 578
  • [9] Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Blesius, Aurore
    Cassier, Philippe A.
    Bertucci, Francois
    Fayette, Jerome
    Ray-Coquard, Isabelle
    Bui, Binh
    Adenis, Antoine
    Rios, Maria
    Cupissol, Didier
    Perol, David
    Blay, Jean-Yves
    Le Cesne, Axel
    [J]. BMC CANCER, 2011, 11
  • [10] Bulusu VR, 2013, P ASCO